Recombinant Human Anti-CD30 x Human Anti-CD64 Bispecific Antibody (scIgG) (SCIGG-H286)

Recombinant Anti-CD30 x Anti-CD64 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD30 and anti-CD64 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget neutrophilscells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD30 & CD64

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)

Targets

Target 1

CD30

Gene ID

943

UniProt ID

P28908

Alternative Names

TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD30 x Human Anti-CD64 Bispecific Antibody (scIgG) (SCIGG-H286). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD30 x Human Anti-CD64 Bispecific Antibody (scIgG) (CAT#: SCIGG-H286)

Specifications

Targets

Customer Reviews and Q&As